Peter S. Sever
Lung Institute(US)Imperial College London(GB)
Publications by Year
Research Areas
Lipoproteins and Cardiovascular Health, Health Systems, Economic Evaluations, Quality of Life, Blood Pressure and Hypertension Studies, Receptor Mechanisms and Signaling, Hormonal Regulation and Hypertension
Most-Cited Works
- → HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials(2014)704 cited
- → Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial(2017)665 cited
- → Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial(2017)587 cited
- → Cognitive Function in a Randomized Trial of Evolocumab(2017)473 cited
- → N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects(2020)256 cited
- → Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis